Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide-based cancer vaccines.

Jean-Pascal Machiels1, Nicolas van Baren, Marie Marchand

  • 1Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Université de Louvain, Brussels, Belgium.

Seminars in Oncology
|October 31, 2002
PubMed
Summary

Cancer patients can be immunized with specific peptides targeting tumor antigens. While generally safe, peptide vaccines show limited efficacy, with less than 20% response rates, necessitating further research for improved cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same author

Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers.

Journal of experimental & clinical cancer research : CR·2026
Same author

Effect of a Single-Session Therapeutic Patient Education Intervention on Physical Activity in Patients Initiating Cancer Therapy: A Randomized Controlled Trial.

JCO oncology practice·2026
Same author

Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma.

Current opinion in oncology·2026
Same author

JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

Future oncology (London, England)·2026

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • T lymphocyte-recognized tumor antigens enable immunization of cancer patients using defined peptides.
  • Differentiation and tumor-specific antigens are present in a substantial number of cancer patients.
  • Pilot studies have primarily focused on melanoma patients, reporting no significant toxicity from peptide vaccination.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of peptide vaccines in cancer patients.
  • To understand the immune mechanisms underlying the therapeutic response to peptide vaccination.

Main Methods:

  • Administration of well-defined tumor antigen peptides to cancer patients.
  • Monitoring for toxicity and clinical response, including tumor regression.

Related Experiment Videos

  • Investigating in vivo immune mechanisms related to vaccine efficacy.

    • Main Results:

    • Peptide vaccination is generally well-tolerated with no major reported toxicity.
    • Clinical efficacy is limited, with response rates below 20% in the studied patient population.
    • A minority of patients experienced complete and long-lasting tumor regressions.

    Conclusions:

    • Peptide vaccines represent a potential strategy for cancer immunotherapy, but their efficacy needs improvement.
    • Further research is required to enhance therapeutic effectiveness, focusing on clinical empiricism and understanding immune responses.
    • Developing effective cancer vaccines necessitates a deeper comprehension of in vivo immune mechanisms.